Mark Birt
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Genetics top 5%
- Genetic Associations and Epidemiology
Papers in
-
- COVID-19 Clinical Research Studies 12
- SARS-CoV-2 and COVID-19 Research 2
- Genetics 8
- Genetic Associations and Epidemiology 7
Mark Birt
21 papers receiving 2.9k citations
Mark Birt's Hit Papers
Peers
Comparison fields: 5 of 101
- Infectious Diseases 1.9k
- Genetics 586
- Applied Microbiology and Biotechnology 35
- Internal Medicine 31
- Hepatology 82
Countries citing papers authored by Mark Birt
This map shows the geographic impact of Mark Birt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Birt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Birt more than expected).
Fields of papers citing papers by Mark Birt
This network shows the impact of papers produced by Mark Birt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Birt. The network helps show where Mark Birt may publish in the future.
No co-authors to show.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 656 |
| 2 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 3 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 4 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 5 | Whole-genome sequencing reveals host factors underlying critical COVID-19 Hit paper breakdown → | 2022 | 233 |
| 6 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 7 | 2021 | 213 | |
| 8 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 125 |
| 9 | Adeno-associated virus 2 infection in children with non-A–E hepatitis Hit paper breakdown → | 2023 | 111 |
| 10 | Genomic investigations of unexplained acute hepatitis in children Hit paper breakdown → | 2023 | 95 |
| 11 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 12 | 2023 | 60 | |
| 13 | 2021 | 26 | |
| 14 | 2023 | 25 | |
| 15 | 2024 | 24 | |
| 16 | 2022 | 8 | |
| 17 | 2024 | 8 | |
| 18 | 2024 | 8 | |
| 19 | 2025 | 5 | |
| 20 | 2025 | 2 |
About Mark Birt
Mark Birt is a scholar working on Infectious Diseases, Genetics, Cardiology and Cardiovascular Medicine, Biochemistry and Hepatology, having authored 22 papers that have together received 3k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (12 papers), Genetic Associations and Epidemiology (7 papers), Viral Infections and Immunology Research (2 papers), Hepatitis B Virus Studies (2 papers), SARS-CoV-2 and COVID-19 Research (2 papers), Hepatitis Viruses Studies and Epidemiology (1 paper), Blood transfusion and management (1 paper) and Total Knee Arthroplasty Outcomes (1 paper). The work is most often cited by research in Infectious Diseases (1.9k citations), Genetics (586 citations), Applied Microbiology and Biotechnology (35 citations), Internal Medicine (31 citations) and Hepatology (82 citations). Mark Birt has collaborated with scholars based in United Kingdom, Austria and Vietnam. Their work appears in journals such as The Lancet, Nature, EClinicalMedicine, Human Genetics and Genomics Advances and The Lancet Diabetes & Endocrinology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.